Journal article
Haptoglobin Genotype as a Determinant of Benefit or Harm from Niacin for Participants with Diabetes
Journal of the American College of Cardiology, Vol.67(21), pp.2553-2554
2016
DOI: 10.1016/j.jacc.2016.03.533
PMID: 27230052
Abstract
One hypothesis that may explain the apparent failure of recent trials of high-density lipoprotein (HDL)-raising therapy is based on the finding that HDL may become proatherogenic under certain circumstances [(1,2)][1], with the proposed result that raising HDL levels in these individuals would be
Details
- Title: Subtitle
- Haptoglobin Genotype as a Determinant of Benefit or Harm from Niacin for Participants with Diabetes
- Creators
- Rabea AslehNina S LevyGheorge DorosTina CostacouJennifer G RobinsonShany BlumHagit GoldensteinWilliam E BodenDebra L SimmonsMegan A LacyGeorge GrunbergerTodd J AndersonAndrew P Levy
- Resource Type
- Journal article
- Publication Details
- Journal of the American College of Cardiology, Vol.67(21), pp.2553-2554
- DOI
- 10.1016/j.jacc.2016.03.533
- PMID
- 27230052
- NLM abbreviation
- J Am Coll Cardiol
- ISSN
- 0735-1097
- eISSN
- 1558-3597
- Language
- English
- Date published
- 2016
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995043102771
Metrics
34 Record Views